Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 233

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 233
---
 reviewing and approving the annual report and accounts and the
half-yearly reports remains with the Board of Directors.

In addition, the Audit Committee
is responsible, within agreed terms of reference, for ensuring compliance with the rules and regulations promulgated by the SEC and the
rules of NASDAQ, and disclosure of information.

The Audit Committee meets
not less than twice a year and otherwise as required.

Nomination Committee

The Nomination Committee is
chaired by Dr. Parker and is currently comprised of Dr. Parker, Dr. de Vries and Dr. Turton. The Nomination Committee assists the Board
of Directors in discharging its responsibilities relating to the composition and make-up of the Board of Directors and any committees
of the Board of Directors. It is responsible for periodically reviewing the Board of Director’s structure and identifying potential
candidates to be appointed as directors or committee members as the need may arise. The Nomination Committee is responsible for evaluating
the balance of skills, knowledge and experience and the size, structure and composition of the Board of Directors and committees of the
Board of Directors, retirements and appointments of additional and replacement directors and committee members and will make appropriate
recommendations to the Board of Directors on such matters.

The Nomination Committee meets not less than once
a year and otherwise as required.

Remuneration Committee

The Remuneration Committee
consists of three members: Dr. de Vries (Chairman), Dr. Turton and Ms. Merchant. During 2023, Dr. Parker served on the Remuneration Committee
until the appointment of Ms. Merchant on January 22, 2024. The Board of Directors has determined that Dr. de Vries and Dr. Turton and
Ms. Merchant are independent.

The Remuneration Committee
of the Board of Directors is responsible, within agreed terms of reference, for establishing a formal and transparent procedure for developing
policy on executive remuneration and setting the remuneration packages of individual directors. This includes agreeing with the Board
of Directors on the framework for remuneration of the executive directors, the company secretary and such other members of our executive
management as it is designated to consider. It is also responsible for determining the total individual remuneration packages of each
director including, where appropriate, bonuses, incentive payments and share options. No director may be involved in any decision as to
his/her own remuneration. The Remuneration Committee ensures compliance with the QCA Code in relation to remun